One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. LAS-INT-06 Study Group.
Duration of therapy is an important factor determining patients' compliance in dermatomycosis clinical practice. We undertook a prospective, randomised, double-blind, parallel group study to investigate the efficacy and tolerability of once daily treatment with terbinafine 1% cream for 1 week, compared to its vehicle, in adult patients with interdigital tinea pedis. Efficacy was assessed in terms of mycological cure, total clinical signs and symptoms scores, and clinical response, 1 day and 1, 5 and 7 weeks after end of treatment. Terbinafine 1% cream was significantly more effective than its vehicle in achieving and maintaining mycological cure for 7 weeks: 91.4% vs. 37.1%, P < 0.001. Terbinafine was also significantly more effective than its vehicle in reducing total clinical signs and symptoms scores, and in achieving clinical response. We conclude that terbinafine 1% cream, applied once daily for 7 days, is an effective and well-tolerated treatment for interdigital tinea pedis in nonimmunocompromised patients. The short duration of treatment needed to achieve mycological cure has important implications for patient compliance and for control of infection within the community.
Korting
H C
HC
Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany. H.C.Korting@lrz.uni-muenchen.de
Tietz
H J
HJ
Bräutigam
M
M
Mayser
P
P
Rapatz
G
G
Paul
C
C
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004821:Epidermophyton / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D014677:Pharmaceutical Vehicles / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D000077291:Terbinafine; D014008:Tinea Pedis / Q000188:drug therapy*; D014249:Trichophyton / Q000187:drug effects
D000935:Antifungal Agents; D009281:Naphthalenes; D014677:Pharmaceutical Vehicles; D000077291:Terbinafine